Product Profiles: Top 20 Oncology Therapy Brands 2011-21
1. Product Profiles: Top 20 Oncology Therapy Brands 2011-21
Report Details:
Published:September 2012
No. of Pages: 157
Price: Single User License – US$11400
The high level of commercial success experienced by the key companies in the oncology market
makes it extremely attractive to drug developers. The treatment of cancer has shifted away from
mass market blockbuster cytotoxic drugs toward a more personalized therapy approach. However,
government austerity packages could see slower commercial growth and larger generic erosion of
key brands.
Features and benefits
•Assess detailed drug information for the leading oncology brands, including detailed clinical trial
information for each approved indication
•Understand the key factors that led to the success of the top 20 oncology therapy brands and the
obstacles that they have encountered
•Gain insight into the clinical and commercial attractiveness for each of the branded drugs and
how this will affect their future sales
Highlights
Targeted therapies comprise 60% of the top 20 brands in 2011 with Roche’s monoclonal antibody
franchise maintaining the top three positions. A potential to demonstrate improved clinical efficacy
with reduced off-target toxicity, combined with an ability to demand higher prices, makes this drug
class clinically and commercially attractive.
An aging cytotoxic market means that cytotoxic brands are becoming less commercially attractive.
In the past few years many of the blockbuster cytotoxics have come off-patent and now face
generic erosion. As developers turn their attention toward new targeted therapies the number of
new cytotoxics entering the market has decreased.
Antihormonal therapies have high clinical attractiveness, but despite strong sales they are limited
to two indications. Effective lifecycle management has ensured that sales remain high despite
patent expiries in almost every major market.
Your key questions answered
•Product profiles and development overviews detailing companies involved and the key clinical
data leading to each approval
•Overview of brand positioning in marketed indications relative to competitors and in terms of
ability to meet unmet needs
•SWOT analysis of each brand in the seven major market top 20
2. •In depth assessment of each brand’s clinical and commercial attractiveness, including
Datamonitor’s drug assessment charts
Get your copy of this report @
http://www.reportsnreports.com/reports/195675-product-profiles-top-20-oncology-therapy-brands-2011-21.html
Major points covered in Table of Contents of this report include
Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
PRODUCT OVERVIEW
Top 20 branded products
Datamonitor’s assessment summary
MARKETED PRODUCT PROFILES
Avastin (bevacizumab; Genentech/Roche/Chugai)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Gleevec (imatinib; Novartis)
Drug profile
Development overview
SWOT analysis
3. Product positioning
Top 20 position
Clinical and commercial attractiveness
Revlimid (lenalidomide; Celgene)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Alimta (pemetrexed; Eli Lilly)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Lupron (leuprolide; Takeda/Abbott)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Eloxatin (oxaliplatin; Sanofi/Yakult Honsha)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Velcade (bortezomib; Takeda/Johnson & Johnson)
Drug profile
Development overview
SWOT analysis
4. Product positioning
Top 20 position
Clinical and commercial attractiveness
Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche/Chugai)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Xeloda (capecitabine; Roche/Genentech/Chugai)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Nexavar (sorafenib; Bayer Schering/Onyx)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Taxotere (docetaxel; Sanofi)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Sutent (sunitinib; Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Sprycel (dasatinib; Bristol-Myers Squibb)
Drug profile
Development overview
SWOT analysis
5. Product positioning
Top 20 position
Clinical and commercial attractiveness
Femara (letrozole; Novartis/Chugai)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Zoladex (goserelin; AstraZeneca)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Tasigna (nilotinib; Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
Temodar (temozolomide; Merck & Co.)
Drug profile
Development overview
SWOT analysis
Product positioning
Top 20 position
Clinical and commercial attractiveness
BIBLIOGRAPHY
Avastin
Journal papers
Websites
Rituxan
Websites
Herceptin
Journal papers
Websites
Gleevec
Journal papers
7. Tasigna
Websites
Temodar
Journal papers
Websites
Appendix
Journal papers
Websites
Other
APPENDIX
Market definition for cancer therapies
Antihormonal therapies by ATC class
Cytotoxic therapies by ATC class
Targeted therapies by ATC class
Datamonitor drug assessment scorecard
Contributing experts
Conferences attended
List of Tables
Table: Drugs included in the top 20 cancer therapy brands ranked according to company-reported
sales in the seven major markets, 2011
Table: Avastin (bevacizumab; Roche/Chugai) – drug profile, 2012
Table: Overview of pivotal trial data for Avastin in cancer, 2012
Table: Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo) – drug profile, 2012
Table: Overview of pivotal trial data for Rituxan in cancer, 2012
Table: Herceptin (trastuzumab; Roche/Chugai) – drug profile, 2012
Table: Overview of pivotal trial data for Herceptin in cancer, 2012
Table: Gleevec (imatinib; Novartis) – drug profile, 2012
Table: Overview of pivotal trial data for Gleevec in cancer, 2012
Table: Revlimid (lenalidomide; Celgene) – drug profile, 2012
Table: Overview of pivotal trial data for Revlimid in cancer, 2012
Table: Alimta (pemetrexed; Eli Lilly) – drug profile, 2012
Table: Overview of pivotal trial data for Alimta, 2012
Table: Lupron (leuprolide; Takeda/Abbott) – drug profile, 2012
Table: Overview of pivotal trial data for Lupron, 2012
Table: Eloxatin (oxaliplatin; Sanofi/Yakult Honsha) – drug profile, 2012
Table: Overview of pivotal trial data for Eloxatin, 2012
Table: Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) – drug profile, 2012
Table: Overview of pivotal trial data for Erbitux in cancer, 2012
Table: Velcade (bortezomib; Takeda/Johnson & Johnson) – drug profile, 2012
Table: Overview of main pivotal trial data for Velcade in cancer, 2012
Table: Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche) – drug profile, 2012
Table: Overview of pivotal trial data for Tarceva in cancer, 2012
8. Table: Xeloda (capecitabine; Roche/Genentech/Chugai) – drug profile, 2012
Table: Overview of pivotal trial data for Xeloda, 2012
Table: Nexavar (sorafenib; Bayer Schering/Onyx) – drug profile, 2012
Table: Overview of pivotal trial data for Nexavar in cancer, 2012
Table: Taxotere (docetaxel; Sanofi) – drug profile, 2012
Table: Overview of pivotal trial data for Taxotere, 2012
Table: Sutent (sunitinib; Pfizer) – drug profile, 2012
Table: Overview of pivotal trial data for Sutent in cancer, 2012
Table: Sprycel (dasatinib; Bristol-Myers Squibb) – drug profile, 2012
Table: Overview of pivotal trial data for Sprycel in cancer, 2012
Table: Femara (letrozole; Novartis/Chugai) – drug profile, 2012
Table: Overview of pivotal trial data for Femara, 2012
Table: Zoladex (goserelin; AstraZeneca) – drug profile, 2012
Table: Overview of pivotal trial data for Zoladex, 2012
Table: Tasigna (nilotinib; Novartis) – drug profile, 2012
Table: Overview of pivotal trial data for Tasigna in cancer, 2012
Table: Temodar (temozolomide; Merck & Co.) – drug profile, 2012
Table: Overview of pivotal trial data for Temodar, 2012
Table: Definition of the cancer market, 2012
Table: Datamonitor’s drug assessment parameters for key oncology therapies
List of Figures
Figure: Datamonitor's drug assessment summary of the top 20 oncology therapy brands, 2012
Figure: Avastin – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Avastin (bevacizumab;
Genentech/Roche/Chugai) in cancer, 2012
Figure: Datamonitor's drug assessment summary of Avastin (bevacizumab;
Genentech/Roche/Chugai), 2012
Figure: Rituxan – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Rituxan (rituximab; Biogen
Idec/Roche/Chugai/Zenyaku Kogyo) in cancer, 2012
Figure: Datamonitor's drug assessment summary of Rituxan (rituximab; Biogen
Idec/Roche/Chugai/Zenyaku Kogyo), 2012
Figure: Herceptin – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Herceptin (trastuzumab; Roche/Chugai) in
cancer, 2012
Figure: Datamonitor's drug assessment summary of Herceptin (trastuzumab;
Genentech/Roche/Chugai), 2012
Figure: Gleevec – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Gleevec (imatinib; Novartis) in cancer, 2012
Figure: Datamonitor's drug assessment summary of Gleevec (imatinib; Novartis), 2012
Figure: Revlimid – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Revlimid (lenalidomide; Celgene) in cancer,
9. 2012
Figure: Datamonitor's drug assessment summary of Revlimid (lenalidomide; Celgene), 2012
Figure: Alimta’s SWOT analysis for cancer, 2012
Figure: Datamonitor's drug assessment summary of Alimta (pemetrexed; Eli Lilly), 2012
Figure: Datamonitor drug assessment summary of Alimta (pemetrexed; Eli Lilly) , 2012
Figure: Lupron’s SWOT analysis for cancer, 2012
Figure: Datamonitor's drug assessment summary of Lupron (leuprolide; Takeda/Abbott), 2012
Figure: Datamonitor drug assessment summary of Lupron (leuprolide; Takeda/Abbott) , 2012
Figure: Eloxatin’s SWOT analysis for cancer, 2012
Figure: Datamonitor's drug assessment summary of Eloxatin (oxaliplatin; Sanofi/Yakult Honsha),
2012
Figure: Datamonitor drug assessment summary of Eloxatin (oxaliplatin; Sanofi/Yakult Honsha) ,
2012
Figure: Erbitux – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Erbitux (cetuximab; Eli Lilly/Bristol-Myers
Squibb/Merck KGaA) in cancer, 2012
Figure: Datamonitor's drug assessment summary of Erbitux (cetuximab; Eli Lilly/Bristol-Myers
Squibb/Merck KGaA), 2012
Figure: Velcade – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Velcade (bortezomib; Takeda/Johnson &
Johnson) in cancer, 2012
Figure: Datamonitor's drug assessment summary of Velcade (bortezomib; Takeda/Johnson &
Johnson), 2012
Figure: Tarceva – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Tarceva (erlotinib; OSI
Pharmaceuticals/Genentech/Roche) in cancer, 2012
Figure: Datamonitor's drug assessment summary of Tarceva (erlotinib; OSI
Pharmaceuticals/Genentech/Roche), 2012
Figure: Xeloda’s SWOT analysis for cancer, 2012
Figure: Datamonitor's drug assessment summary of Xeloda (capecitabine;
Roche/Genentech/Chugai), 2012
Figure: Datamonitor drug assessment summary of Xeloda (capecitabine;
Roche/Genentech/Chugai) , 2012
Figure: Nexavar – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Nexavar (sorafenib; Bayer Schering/Onyx) in
cancer, 2012
Figure: Datamonitor's drug assessment summary of Nexavar (sorafenib; Bayer Schering/Onyx),
2012
Figure: Taxotere’s SWOT analysis for cancer, 2012
Figure: Datamonitor's drug assessment summary of Taxotere (docetaxel; Sanofi), 2012
Figure: Datamonitor drug assessment summary of Taxotere (docetaxel; Sanofi) , 2012
Figure: Sutent – SWOT analysis in cancer, 2012
10. Figure: Datamonitor’s drug assessment summary for Sutent (sunitinib; Pfizer) in cancer, 2012
Figure: Datamonitor's drug assessment summary of Sutent (sunitinib; Pfizer), 2012
Figure: Sprycel – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Sprycel (dasatinib; Bristol-Myers Squibb) in
cancer, 2012
Figure: Datamonitor's drug assessment summary of Sprycel (dasatinib; Bristol-Myers Squibb),
2012
Figure: Femara’s SWOT analysis for cancer, 2012
Figure: Datamonitor's drug assessment summary of Femara (letrozole; Novartis/Chugai), 2012
Figure: Datamonitor drug assessment summary of Femara (letrozole; Novartis/Chugai) , 2012
Figure: Zoladex’s SWOT analysis for cancer, 2012
Figure: Datamonitor's drug assessment summary of Zoladex (goserelin; AstraZeneca), 2012
Figure: Datamonitor drug assessment summary of Zoladex (goserelin; AstraZeneca) , 2012
Figure: Tasigna – SWOT analysis in cancer, 2012
Figure: Datamonitor’s drug assessment summary for Tasigna (nilotinib; Novartis) in cancer, 2012
Figure: Datamonitor's drug assessment summary of Tasigna (nilotinib; Novartis), 2012
Figure: Temodar’s SWOT analysis for cancer, 2012
Figure: Datamonitor's drug assessment summary of Temodar (temozolomide; Merck & Co.), 2012
Figure: Datamonitor drug assessment summary of Temodar (temozolomide; Merck & Co.) , 2012
Contact: sales@reportsandreports.com for more information.
